Tag: TipRanks.com

Posted on

Article: H.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)

Article - Media

H.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)

Christine Brown

SmarterAnalyst, 1 May 2020

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Pluristem (PSTI), with a price target of $15.50. The company’s shares closed last Thursday at $9.17.

According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -0.7% and a 36.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, IntelGenx Technologies, and Corvus Pharmaceuticals.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

 

Posted on

Article: H.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)

Article - Media

H.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)

Christine Brown

SmarterAnalyst, 1 May 2020

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on CareDx (CDNA), with a price target of $40.00. The company’s shares closed last Thursday at $25.38.

According to TipRanks.com, Chen is a 5-star analyst with an average return of 14.1% and a 43.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

RELATED:Video: Ekso Bionics Killed by Naked Short Sellers – Thank You, HCWainwright for Front-Running Their Death

Posted on

Article: Vertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright

Article - Media

Vertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright

Austin Angelo

SmarterAnalyst, 30 April 2020

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (), with a price target of $295.00. The company’s shares closed last Wednesday at $251.05.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 8.9% and a 48.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Posted on

Article: H.C. WAINWRIGHT STICKS TO ITS BUY RATING FOR EKSO BIONICS (EKSO)

Article - Media

H.C. WAINWRIGHT STICKS TO ITS BUY RATING FOR EKSO BIONICS (EKSO)

Catie Powers

Markets.co, 31 October 2019

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a rating on EKSO BIONICS ( – Research Report) today and set a price target of $1.20. The company’s shares closed last Monday at $0.66, close to its 52-week low of $0.48.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.
RELATED:

THE DOLLAR HAS NO INTRINSIC VALUE : DO YOUR ASSETS?